MAP to Provide Access to Nilotinib, for Patients With HES

Condition:   Hypereosinophilic Syndrome (HES) Intervention:   Drug: Nilotinib Sponsor:   Novartis Pharmaceuticals Available

Source: ClinicalTrials.gov - August 5, 2020 Category: Research Source Type: clinical trials